This study found that smoking increased the risk of mortality among cancer survivors, even after adjusting for cancer type and stage,” researchers reported.

Incidence and mortality from renal cancer may double by 2050, according to a study published in European Urology.

Adjuvant ensartinib improves disease-free survival compared to placebo following complete resection of ALK-positive non-small cell lung cancer.

In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo.

Long preoperative chemo elicited more pathologic complete responses than short preoperative chemo in PDAC, but no difference in EFS was seen.

First-line treatment with disitamab vedotin and toripalimab improved outcomes over chemotherapy in patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma.

The Inflation Reduction Act has decreased Medicare Part D expenditures and the total cost of care under the Enhancing Oncology Model but has not reduced total drug spending, data suggest.

Therapeutic plasma exchange may allow patients with advanced melanoma to overcome immune checkpoint inhibitor resistance, data suggest.

Adjuvant cemiplimab may reduce the risk of second primary tumors in patients with high-risk cutaneous squamous cell carcinoma, data suggest.

The incidence rates for invasive lobular carcinoma increased from 2012 to 2021 for all racial and ethnic groups, according to a study published in Cancer.

Dato-DXd improved outcomes over chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who were ineligible for immunotherapy.